



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: I hereby certify that this) paper is being deposited ANIL GULATI with the United States Postal Service with suffi-Serial No.: 10/691,915 cient postage, as first class mail, in an envelope Filed: October 23, 2003 addressed to: Commissioner for Patents For: METHOD AND COMPOSITION FOR P.O. Box 1450 PREVENTING AND TREATING SOLID Alexandria, VA 22313-1450 TUMORS Dated: March 19, 2004 Attorney Docket No. 27611/38802A Group Art Unit: 1614 Examiner: Unassigned James J. Napoli Registration No. 32,361) Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to his duty of disclosure under 37 C.F.R. §1.56, applicant hereby brings to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicant encloses a completed Form PTO-1449 listing the possible pertinent patents and publications and a copy of each patent and publication.

This Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and, to



applicant's knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Information Disclosure Statement shall be considered by the Patent Office.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

Βv

James J. Napoli √

(Registration No. 32,361) Attorneys for Applicants 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606 (312) 474-6300

Chicago, Illinois March 19, 2004 RADEM! Complete if Known orm 1449PTO Application Number 10/691,915 INFORMATION DISCLOSURE October 23, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Anil Gulati Group Art Unit 1614 (use as many sheets as necessary) Unassigned **Examiner Name** 27611/38802A Sheet 1 of 1 Attorney Docket Number

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY		
	tials* No. 5,6	5,612,359	03/18/1997		
		5,811,416	09/22/1998		
		US2002/0082285	03/18/1997		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY		
		WO 96/19233 (PCT) .~	06/27/1996		
		WO 01/91736 (PCT) /	12/06/2001		
		WO 03/009805 (PCT)	02/06/2003		
		WO 03/045434 (PCT)	06/05/2003		
		EP 0- 815 870 (EPO)	01/07/1998		

		OTHER PRIOR ART - NONPATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		K. Matsumaru et al., J. Gastroenterol, 32, 164-170 (1997).		
		A.E. Duggan et al., Aliment Pharmacol Ther, 13, 631-635 (1999).		
		A.S.C. Fabricio et al., British Journal of Pharmacology, 125, 542-548 (1998).		
		K. Parfitt (ed)., "Martindale The complete drug reference (32nd Edition)," Pharmaceutical Press, 1999.		
		S. Bhalla et al., <i>Peptides</i> , 23, 1837-1845 (2002).		
		H.N. Bhargava et al., The Journal of Pharmacology and Experimental Therapeutics, Vol. 252, No. 3, 901-907 (1990).		
		C. Wu, Exp. Opin. Ther. Patents, 10(11), 1653-1668 (2000).		
		M.F. Jarvis et al., European Journal of Pharmacology, 388, 29-35 (2000).		
		G. Davar et al., NeuroReport, 9, 2279-2283 (1998).		
		·		

Examiner Date	
Signature Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.